The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ruxolitinib is approved by the European Commission for the treatment of patients with SR-GvHD
On May 5, 2022, the European Commission announced the approval of ruxolitinib, a JAK1/2 inhibitor, for treatment of patients aged ≥12 years with acute or chronic graft-versus-host disease (GvHD) who have inadequate response to corticosteroids or other systemic therapies.1 Previously, patients in Europe had no approved agents for steroid refractory (SR)-GvHD.
This announcement follows the positive opinion granted by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) for ruxolitinib in March 2022, which was based on the results of the phase III REACH2 (NCT02913261) and REACH3 (NCT03112603) trials.
In the REACH3 trial, ruxolitinib showed an overall response rate at Week 24 of 49.7%, compared with 25.6% for the best available therapy, in patients with SR-chronic GvHD. The best overall response rate achieved in this trial in the ruxolitinib group was 76.4% versus 60.4% in the best available therapy group. The New England Journal of Medicine published the results of the REACH3 trial in July 2021.2
Ruxolitinib has already been approved by the U.S. Food and Drug administration (FDA) for treating patients ≥12 years with SR-acute GvHD (in 2019) and also for those ≥12 years with chronic GvHD who have previously received 1–2 lines of therapy (in 2021).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content